Monday, April 27, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Apr 24, 2026
Chutes & Ladders—Helus shuffles out CEO after two months, adds experience to science board
background ▾
- •Helus Pharma CEO Michael Cola departed after two months, prompting return of co-founder Eric So as interim CEO and recruitment of Langer and Brannan to strengthen scientific credibility
Helus PharmaPfizerParatus SciencesVyvansePS-1001
→ Read original articlePolicy•Endpoints News•Apr 24, 2026
Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejection
background ▾
- •CHMP positive opinion for tolebrutinib in MS represents a significant regulatory win in Europe despite FDA rejection, demonstrating distinct regulatory pathways and risk-benefit frameworks between jurisdictions
- •FDA's CRL suggests potential safety or efficacy concerns that Sanofi must address; the EU's backing indicates the compound retains therapeutic value for certain patient populations
- •Watch for EMA final approval timeline, FDA resubmission strategy, and commercial launch planning in Europe; also monitor whether additional data could resolve FDA's concerns in potential resubmission
Sanofitolebrutinib
→ Read original articlePolicy•STAT News•Apr 27, 2026
Opinion: I’m a fourth-year med student, but I only learned one historical example of medical racism
background ▾
- •The paused Guinea-Bissau hepatitis B trial exemplifies a persistent pattern: since the 1990s, pharma companies have systematically moved trials to resource-limited settings overseas to reduce costs and access treatment-naïve populations, often with inadequate informed consent.
- •Historical precedent includes Pfizer's 1996 Nigeria meningitis drug trial (fatal outcomes), 1990s HIV placeholder-controlled trials, and decades of experimentation in U.S. territories—yet these ethics breaches remain absent from standard medical school curricula, leaving future physicians unprepared to recognize or prevent such inequities.
- •Watch for: whether regulatory agencies strengthen trial oversight in low-income countries, whether medical education integrates this history into ethics training, and whether institutional accountability mechanisms move beyond 'measured language' from bodies like WHO to concrete enforcement.
Pfizerhepatitis B vaccinemeningitis drug (experimental)zidovudine
→ Read original articlePolicy•Fierce Pharma•Apr 27, 2026
FDA snubs AbbVie's prospective Botox heir amid series of manufacturing-related CRLs
background ▾
- •FDA rejected applications from AbbVie and Grace Therapeutics due to manufacturing concerns, not clinical efficacy or safety data—a potentially correctable but operationally significant obstacle
- •The rejection targets a Botox competitor, meaning AbbVie loses a near-term opportunity in the lucrative aesthetics/neurotoxin market where it already dominates
- •Watch for resubmission timelines and whether manufacturing issues reflect systemic problems at either company's facilities or are product-specific and readily addressable
AbbVieGrace TherapeuticsBotox
→ Read original articlePolicy•Fierce Pharma•Apr 27, 2026
Sanofi gains long-awaited win for tolebrutinib as EU regulator endorses MS drug for approval
background ▾
- •CHMP positive opinion removes a major regulatory barrier and substantially increases probability of EU market access for tolebrutinib in MS
- •This victory follows prior setbacks, suggesting Sanofi has successfully addressed previous regulatory concerns and strengthened the drug's risk-benefit profile
- •Watch for: final European Commission approval timeline, competitive positioning against other BTK inhibitors (ibrutinib, zanubrutinib) and newer MS therapies, and early uptake metrics in European markets
Sanofitolebrutinib
→ Read original articleMarket Access
Market Access•Fierce Biotech•Apr 25, 2026
Thermo Fisher sees higher Q1 earnings amid strong biopharma demand
background ▾
- •Thermo Fisher's core biopharma services business accelerated 7% YoY, signaling robust customer demand and strong biotech funding environment heading into mid-2024
- •Clario acquisition integration began contributing immediately ($30M in Q1 revenue), validating the strategic rationale for clinical trial data capabilities
- •Company positioned AI and autonomous laboratory infrastructure as material growth catalysts, with CEO explicitly linking this to increased biotech funding interest and drug pipeline productivity
Thermo Fisher ScientificClarioNvidia
→ Read original articleMarket Access•Fierce Biotech•Apr 24, 2026
After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?
background ▾
- •In vivo CAR-T dealmaking is entering a consolidation endgame: only a handful of acquisition-ready biotechs remain, with Umoja Biopharma identified as the most obvious remaining target despite existing AbbVie optionality
- •Big Pharmas are willing to pay premium prices (often 50%+ above typical early-stage valuations) because in vivo CAR-T's dual potential in oncology and autoimmune indications justifies the investment as defensive positioning against platform disruption
- •Watch for acquisition interest shifting toward Chinese players (e.g., Starna Therapeutics) as Western biotech targets dry up, and monitor how AbbVie's existing options on Umoja's assets affect competitive bidding dynamics
Eli LillyKelonia TherapeuticsOrna TherapeuticsUB-VV400/410UB-VV111Yescarta
→ Read original articleMarket Access•Fierce Pharma•Apr 27, 2026
Travere’s launchpad positions Filspari for fast rise toward blockbuster sales: analyst
background ▾
- •Analysts forecast $3.1 billion peak sales for Filspari based on Travere's existing sales force and payer infrastructure
- •Established authorization criteria and commercial relationships are expected to accelerate the launch timeline
Travere TherapeuticsFilspari
→ Read original articleMarket Access•Fierce Pharma•Apr 27, 2026
Pfizer drafts Fernando Mendoza as new face of its ‘game of inches’ cancer campaign
background ▾
- •Pfizer is expanding its cancer awareness marketing through celebrity partnerships and sports-themed messaging
Pfizer
→ Read original articleMarket Access•Fierce Pharma•Apr 27, 2026
Genentech wants ‘All Eyes on DME’ as it taps Damon Wayans for humor-laced campaign
background ▾
- •Genentech is investing in DME patient awareness and education through a celebrity-driven consumer campaign
GenentechRoche
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Apr 24, 2026
WCG acquires The Contract Network in bid to streamline clinical trial execution
background ▾
- •WCG's acquisition of The Contract Network extends its AI capabilities in clinical trial site enablement and contract/budget workflows—areas historically prone to delays.
- •The move reflects intensifying CRO competition to deploy AI across trial operations; comparable recent initiatives include Fortrea's AI engine launch and partnerships between AstraZeneca/Astellas and Evinova.
WCGThe Contract NetworkFortrea
→ Read original articleClinical Trials•Endpoints News•Apr 24, 2026
Exclusive: UC Berkeley startup bets on jumping genes for GLP-1 gene therapy
background ▾
- •Novel gene therapy strategy using jumping genes to enable endogenous GLP-1 production represents a differentiated approach to the weight loss market, potentially addressing adherence limitations of current blockbuster drugs
- •The regulatory pathway and safety profile of transposable element-based therapeutics in humans remains unproven, requiring substantial preclinical and IND-enabling work
UC BerkeleyGLP-1
→ Read original article